DimopoulosM.A., KastritisE., RosinolL., BiadèJ., LudwingH.. Pathogenesis and treatment of renal failure in multiple myeloma.Leukemia2008; 22(8): 1485–93. Epub 2008 Jun 5.
3.
Basic-JukicN., KesP., LabarB.. Myeloma kidney: pathogenesis and treatment.Acta Med Croatica2001; 55(4-5): 169–75.
4.
BoccadoroM., CavoM., PalumboA.Bortezomib nel mieloma multiplo. Edizione speciale 2010.Il Pensiero Scientifico Editore2010; 56–60.
5.
LudwigH., AdamZ., HajekR.. Bortezomib-doxorubicin-dexamethasone (BDD) in patients with acute light chain induced renal failure (ARF) in multiple myeloma (MM). Final results of a phase II study.Blood2009; 114: Abs 3862.
6.
RoussouM., KastritisE., ChristoulasD.. Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents.Blood2009; 114: Abs 955.
